Insurance claims data showed that patients with autoimmune disorders who took Janus kinase (JAK) inhibitors had lower rates of age-related macular degeneration (AMD), hinting that the drugs might treat the common eye disease.
The journal Pain has shown geographic differences in arthritis-attributable pain, arthritis-related outcomes mostly clustered in the Deep South and Appalachia, while severe arthritis pain is more prevalent in the Southwest, Pacific Northwest, Georgia, Florida, and Maine.
Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report. This is the 7th year in a row they have held this spot.The top 5 rheumatology hospitals are largely the same as last year (with some minor shuffling) and includes the Johns Hopkins Hospital, Cleveland Clinic, Hospital for Special Surgery (HSS), Brigham Hospital, and Mayo Clinic.
Medscape has published an overview to the 2024 updated recommendations for the treatment of systemic sclerosis (SSc) presented in Vienna at EULAR 2024 by Professor Francesco Del Galdo, MD, PhD on behalf of a 27 member task force.
The American College of Rheumatology (ACR) shared the following initial reaction to the proposed CY 2025 Medicare Physician Fee Schedule (MPFS) and Quality Payment Program rule.
Systemic sclerosis sine scleroderma (ssSSc), which accounts for nearly 10% of systemic sclerosis (SSc) patients and was first described in 1962, is a subset of SSc.
Autoimmune liver diseases (ALDs), including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC), are complex conditions involving the liver's immune-mediated damage. These diseases are increasingly prevalent, but their pathogenesis remains largely unclear.
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Two prominent medical journals this week published new insights into the pathogenesis of systemic lupus erythematosus (SLE), with both inidicating promient roles for T cells in what is a classically viewed as a humoral (B cell) disorder.
Among women followed for upwards of 25 years, those who ate relatively large amounts of "ultraprocessed" foods -- such as soft drinks, frozen pizzas, and mass-produced baked goods -- developed systemic lupus erythematosus at more than 50% greater rates than those with relatively low consumption, a new analysis of Nurses' Health Study data showed.
Cartesian Therapeutics, has announced their first-in-class mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) therapy has been given to the first systematic lupus erythematosus (SLE). patient in a Phase 2 open-label clinical trial.
A retrospective cohort study of biological disease-modifying antirheumatic drugs (bDMARDs) persistence in rheumatoid arthritis (RA) patients with chronic kidney disease (CKD), shows the 3 year survicval to be under 50% but that all studied biologics were nearly equivalents with regard to safety and efficacy.
Despite the clinical similarities and treatment differences between giant cell arteritis (GCA polymyalgia rheumatica (PMR), confusion exists regarding the impact of overlapping disorders. A large cohort study shows that GCA patients with PMR symptoms are more apt to have recalcitrant disease, more relapses and longer duration of glucocorticoid (GC), along with higher GC doses.
An economic evaluation of 25 099 rheumatoid arthritis patients found that treatment with biosimilar disease-modifying antirheumatic drugs (DMARDs) were cost-effective compared with the conventional DMARD, leflunomide. Does this suggest RA treatment guidelines need to be amended to allow biosimilars use immediately after the failure of methotrexate?
In patients with clinically stable systemic lupus erythematosus (SLE) and lupus nephritis, the withdrawal of mycophenolate mofetil was not significantly inferior to mycophenolate maintenance, but MMF withdrawal had numerically more reactivations, while MMF maintenance had more infections.
